Market closed
Syndax Pharmaceuticals/$SNDX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Syndax Pharmaceuticals
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Ticker
$SNDX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
184
Website
SNDX Metrics
BasicAdvanced
$1.1B
Market cap
-
P/E ratio
-$3.62
EPS
0.92
Beta
-
Dividend rate
Price and volume
Market cap
$1.1B
Beta
0.92
52-week high
$25.34
52-week low
$12.79
Average daily volume
2.4M
Financial strength
Current ratio
6.986
Quick ratio
6.923
Long term debt to equity
0.001
Total debt to equity
0.233
Interest coverage (TTM)
-1,726.95%
Management effectiveness
Return on assets (TTM)
-48.67%
Return on equity (TTM)
-81.88%
Valuation
Price to revenue (TTM)
65.95
Price to book
3
Price to tangible book (TTM)
3
Price to free cash flow (TTM)
-4.076
Growth
Earnings per share change (TTM)
39.84%
3-year revenue growth (CAGR)
5.80%
3-year earnings per share growth (CAGR)
25.59%
What the Analysts think about SNDX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Syndax Pharmaceuticals stock.
SNDX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SNDX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SNDX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Syndax Pharmaceuticals stock?
Syndax Pharmaceuticals (SNDX) has a market cap of $1.1B as of December 21, 2024.
What is the P/E ratio for Syndax Pharmaceuticals stock?
The price to earnings (P/E) ratio for Syndax Pharmaceuticals (SNDX) stock is 0 as of December 21, 2024.
Does Syndax Pharmaceuticals stock pay dividends?
No, Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next Syndax Pharmaceuticals dividend payment date?
Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.